Literature DB >> 7519533

Persistent reduction of complement receptor 3 alpha-chain expressing mononuclear blood cells and transient inhibitory serum factors in Whipple's disease.

T Marth1, M Roux, A von Herbay, S C Meuer, G E Feurle.   

Abstract

Several small studies have indicated an impaired cell mediated immune response as a possible cause for the delayed elimination of the bacteria in Whipple's disease. A specific defect, however, has not been defined. We examined the expression of cell surface molecules and mitogenic responses of peripheral blood mononuclear cells in 27 patients with Whipple's disease at different disease stages by indirect immunofluorescence and by measurement of [3H]thymidine incorporation, respectively. E-rosette formation and cutaneous reaction to seven recall antigens were determined. Matched healthy donors served as controls. We found a significantly reduced number of cells expressing the complement receptor 3 alpha-chain (= CD11b) in all patients. In florid disease, the number of activated cells (in particular CD58 positive cells) was increased and CD4/CD8 ratios were diminished. Proliferation to phytohemagglutinin and to sheep red blood cells was reduced at all stages of the disease. Serum of control persons reversed this decreased responsiveness especially in patients with active disease. Skin reaction was hypoergic in all patients. Determination of CD58 positive cells increased in patients with active disease may be useful to define the activity of the disease and the duration necessary for treatment. Transient inhibiting serum activities may impair the CD2/CD58 interaction. The reduction of cells expressing CD11b, the decreased proliferation, and the cutaneous hypoergy indicate a persisting defect of cell mediated immunity in vivo and in vitro. These defects may contribute to the impaired ability of patients with Whipple's disease to eliminate bacteria.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7519533     DOI: 10.1006/clin.1994.1134

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  16 in total

Review 1.  Whipple's disease.

Authors:  R N Ratnaike
Journal:  Postgrad Med J       Date:  2000-12       Impact factor: 2.401

Review 2.  Whipple's disease revisited.

Authors:  S A Misbah; N P Mapstone
Journal:  J Clin Pathol       Date:  2000-10       Impact factor: 3.411

Review 3.  The diagnosis and treatment of Whipple's disease.

Authors:  T Marth
Journal:  Curr Allergy Asthma Rep       Date:  2001-11       Impact factor: 4.806

Review 4.  Whipple's disease and "Tropheryma whippelii".

Authors:  F Dutly; M Altwegg
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

Review 5.  Whipple's disease: a macrophage disease.

Authors:  Benoît Desnues; Melanie Ihrig; Didier Raoult; Jean-Louis Mege
Journal:  Clin Vaccine Immunol       Date:  2006-02

6.  Rare but not so rare: The evolving spectrum of Whipple's disease.

Authors:  J M Conly; B L Johnston
Journal:  Can J Infect Dis       Date:  2001-05

Review 7.  Macrophage-related diseases of the gut: a pathologist's perspective.

Authors:  Xavier Sagaert; Thomas Tousseyn; Gert De Hertogh; Karel Geboes
Journal:  Virchows Arch       Date:  2012-05-11       Impact factor: 4.064

8.  Detection of Tropheryma whippelii DNA in a patient with AIDS.

Authors:  M Maiwald; H J Meier-Willersen; M Hartmann; A von Herbay
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

9.  Environmental occurrence of the Whipple's disease bacterium (Tropheryma whippelii).

Authors:  M Maiwald; F Schuhmacher; H J Ditton; A von Herbay
Journal:  Appl Environ Microbiol       Date:  1998-02       Impact factor: 4.792

10.  Epidemiology of Whipple's Disease in the USA Between 2012 and 2017: A Population-Based National Study.

Authors:  Jamie Ann Elchert; Emad Mansoor; Mohannad Abou-Saleh; Gregory S Cooper
Journal:  Dig Dis Sci       Date:  2018-11-28       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.